<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:department>Community-Based Medicine</gtr:department><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/1A07ADBE-1F53-4B0F-B414-EF81C965796C"><gtr:id>1A07ADBE-1F53-4B0F-B414-EF81C965796C</gtr:id><gtr:firstName>Paddy</gtr:firstName><gtr:surname>Horner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3F38FC7E-CA1A-455E-A72D-1438369CFA31"><gtr:id>3F38FC7E-CA1A-455E-A72D-1438369CFA31</gtr:id><gtr:firstName>Kate</gtr:firstName><gtr:surname>Soldan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/00FD6AA2-05F7-496D-B825-61F2CD8CDD16"><gtr:id>00FD6AA2-05F7-496D-B825-61F2CD8CDD16</gtr:id><gtr:firstName>A E</gtr:firstName><gtr:surname>Ades</gtr:surname><gtr:orcidId>0000-0001-7822-3552</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A58E7E60-29A0-4CA7-BF81-7788E4340366"><gtr:id>A58E7E60-29A0-4CA7-BF81-7788E4340366</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Macleod</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5033A559-126A-4C8C-9798-8FDCC4C74ACD"><gtr:id>5033A559-126A-4C8C-9798-8FDCC4C74ACD</gtr:id><gtr:firstName>Nicky</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Welton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/79A02A17-0A98-4424-A965-C910B46F56D4"><gtr:id>79A02A17-0A98-4424-A965-C910B46F56D4</gtr:id><gtr:firstName>Daniela</gtr:firstName><gtr:surname>De Angelis</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/87849B37-5114-4014-8926-8069E55C6D2B"><gtr:id>87849B37-5114-4014-8926-8069E55C6D2B</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:surname>Simms</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0801947"><gtr:id>CA589B3C-DF1D-465D-89D3-2B8551332AA3</gtr:id><gtr:title>A natural history model of Chlamydia Trachomatis infection: incidence and prevalence of preventable complications</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0801947</gtr:grantReference><gtr:abstractText>The National Chlamydia Screening Programme has now been rolled out to all Primary Care Trusts in England. However, the extent of the health gain that can be achieved by early detection and treatment of chlamydial infection remains unclear. Estimates of the numbers of complications that could be prevented in two recent UK models were based on entirely different sources of data, and neither met the requirement that they should be both internally consistent and consistent with all the data. This project will scrutinise the full range of prospective and retrospective evidence, consider potential biases in it, and reach a consensus view on its interpretation. New statistical modelling techniques will be deployed to combine information from disparate sources, adjusting for bias and using all relevant studies and routine surveys, in order to make the most accurate possible estimates of the complications of chlamydia and the potential gains from screening. While oriented to CT policy in the UK, the research will introduce an approach and scientific results that could be applied in other industrialised countries, and to other public health conditions.</gtr:abstractText><gtr:technicalSummary>The effectiveness and cost-effectiveness of screening for Chlamydia trachomatis in the UK has been assessed in recent modeling studies. Cost-effectiveness is highly sensitive to assumptions regarding the frequency of major preventable complications, pelvic inflammatory disease, ectopic pregnancy, infertility, and neonatal conjunctivitis and pneumonia. There is however no consensus on these key parameters - or even on which evidence sources should be used to inform them. The proposed research aims to obtain a consensus interpretation of the existing evidence, and internally consistent and externally validated estimates of the incidence and prevalence of Chlamydia trachomatis infection and its complications. This will be based on systematic analysis of all available evidence identified under a strict protocol for inclusion, scrutiny of studies to identify potential sources of bias, and quantification of potential biases by epidemiologists with expertise in the field. Statistical modelling via Bayesian multi-parameter evidence synthesis will be used model the natural history of CT, incorporating all sources of data and uncertainty. The model will be thoroughly assessed for consistency with the data. The results of the model will be available for future cost-effectiveness analyses of Chlamydia trachomatis screening in the UK and elsewhere, and for dynamic disease transmission modelling.</gtr:technicalSummary><gtr:fund><gtr:end>2011-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2009-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>205119</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Int Soc STD, Quebec 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4E91C662-EE1F-4063-BEB3-5C3652F9CAB8</gtr:id><gtr:impact>Price MJ , Ades AE, De Angelis D, Welton NJ, Macleod J, Soldan K, Turner K, Simms I, Horner PJ. Risk of Pelvic Inflammatory Disease following Chlamydia trachomatis: Analysis of prospective studies with a multistate model. International Society for Sexually Transmitted Disease Research, 2011, Quebec City, Canada (Poster presentation)

.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Amsterdam 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>12BCA21F-E6CF-4591-BE9B-B4639DCAA7EF</gtr:id><gtr:impact>Price MJ, Ades AE, De Angelis D, Welton NJ, Macleod J, Soldan K, Turner K, Simms I, Horner PJ. How much Tubal Factor Infertility is caused by Chlamydia? Estimates based on serological evidence corrected for sensitivity and specificity. 7th meeting of the European Society for Chlamydia, 2012, Amsterdam, Holland (Oral presentation)

.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HPA 2011</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DC274C11-F990-4D98-A423-913DE8F8B90E</gtr:id><gtr:impact>Price MJ , Ades AE, De Angelis D, Welton NJ, Macleod J, Soldan K, Turner K, Simms I, Roberts T, Horner PJ. A multi-parameter evidence synthesis of the natural history of Chlamydia Trachomatis infection in Women, Health Protection Agency Sexually Transmitted Diseases Unit, 2011, Colindale, London (Invited Talk).

.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Stockholm 2012</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>26CDA7C4-0D8C-4313-8424-038A68FDC63D</gtr:id><gtr:impact>Price MJ, Ades AE, De Angelis D, Welton NJ, Macleod J, Soldan K, Turner K, Simms I, Roberts T, Horner PJ. Bayesian Multi-parameter Evidence Synthesis for the natural history of Chlamydia. European Centre for Disease Control Expert meeting - Chlamydia control in Europe, 2012, Stockholm, Sweden (invited participant, oral presentation).

This was a gathering of leading European experts, by invitation only</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Inst Soc Std Quebec 2011 Incidence</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B20449D4-6A17-4ABF-92B6-48F18AF8DACA</gtr:id><gtr:impact>Price MJ, Ades AE, De Angelis D, Welton NJ, Macleod J, Soldan K, Turner K, Simms I, Horner PJ. Duration of Chlamydia trachomatis infection and its incidence and prevalence in women in the United Kingdom: a multi-parameter synthesis. International Society for Sexually Transmitted Disease Research, 2011, Quebec City, Canada (Poster presentation)

.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Int Soc Std Quebec 2011, Serology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2032FBA0-7EF0-4846-BBD8-5982FA5EEFE8</gtr:id><gtr:impact>Price MJ, Ades AE, De Angelis D, Welton NJ, Macleod J, Soldan K, Turner K, Simms I, Horner PJ. How much Tubal Factor Infertility is caused by Chlamydia? Estimates based on serological evidence corrected for sensitivity and specificity. International Society for Sexually Transmitted Disease Research, 2011, Quebec City, Canada (Poster presentation)

.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Health Protection Research Unit</gtr:description><gtr:fundingOrg>Public Health England</gtr:fundingOrg><gtr:id>6DDDE1FF-CE57-403D-899D-CE515F971125</gtr:id><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A9B3EEFF-ACB7-48B7-AD47-E6334CB6AD1F"><gtr:id>A9B3EEFF-ACB7-48B7-AD47-E6334CB6AD1F</gtr:id><gtr:title>Time to take causation seriously.</gtr:title><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/88a9be9ded32871e2b85bf23f979c098"><gtr:id>88a9be9ded32871e2b85bf23f979c098</gtr:id><gtr:otherNames>Price, M J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9F4593EA-148B-411E-8B3A-10F51F94428C"><gtr:id>9F4593EA-148B-411E-8B3A-10F51F94428C</gtr:id><gtr:title>Mixture-of-exponentials models to explain heterogeneity in studies of the duration of Chlamydia trachomatis infection.</gtr:title><gtr:parentPublicationTitle>Statistics in medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b5f8e247f0398fb1f6fc73be32a5ab2"><gtr:id>6b5f8e247f0398fb1f6fc73be32a5ab2</gtr:id><gtr:otherNames>Price MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0277-6715</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/620DA4E1-2ACB-4E46-A519-4C8F48B2A1F0"><gtr:id>620DA4E1-2ACB-4E46-A519-4C8F48B2A1F0</gtr:id><gtr:title>Incidence of Chlamydia trachomatis infection in women in England: two methods of estimation.</gtr:title><gtr:parentPublicationTitle>Epidemiology and infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b5f8e247f0398fb1f6fc73be32a5ab2"><gtr:id>6b5f8e247f0398fb1f6fc73be32a5ab2</gtr:id><gtr:otherNames>Price MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0950-2688</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1E22A2A7-BB47-41AB-8F5E-0BF14C563185"><gtr:id>1E22A2A7-BB47-41AB-8F5E-0BF14C563185</gtr:id><gtr:title>Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b5f8e247f0398fb1f6fc73be32a5ab2"><gtr:id>6b5f8e247f0398fb1f6fc73be32a5ab2</gtr:id><gtr:otherNames>Price MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9C0BE574-391F-47DA-8D27-D2ABB477115B"><gtr:id>9C0BE574-391F-47DA-8D27-D2ABB477115B</gtr:id><gtr:title>The natural history of Chlamydia trachomatis infection in women: a multi-parameter evidence synthesis.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b5f8e247f0398fb1f6fc73be32a5ab2"><gtr:id>6b5f8e247f0398fb1f6fc73be32a5ab2</gtr:id><gtr:otherNames>Price MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5AC7F85B-3952-4958-8BE2-F5D2D429DD34"><gtr:id>5AC7F85B-3952-4958-8BE2-F5D2D429DD34</gtr:id><gtr:title>Risk of reproductive complications following chlamydia testing.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b5f8e247f0398fb1f6fc73be32a5ab2"><gtr:id>6b5f8e247f0398fb1f6fc73be32a5ab2</gtr:id><gtr:otherNames>Price MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/27084195-6F8B-4B6F-B20B-1EEBF9C35AAA"><gtr:id>27084195-6F8B-4B6F-B20B-1EEBF9C35AAA</gtr:id><gtr:title>Proportion of Tubal Factor Infertility due to Chlamydia: Finite Mixture Modeling of Serum Antibody Titers.</gtr:title><gtr:parentPublicationTitle>American journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/be634fac835e6c6b3a8ab2f90cde0628"><gtr:id>be634fac835e6c6b3a8ab2f90cde0628</gtr:id><gtr:otherNames>Ades AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9262</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5753A3D9-643F-460E-B9D5-17025C5E822A"><gtr:id>5753A3D9-643F-460E-B9D5-17025C5E822A</gtr:id><gtr:title>P3.013 The Role of Chlamydia in Pelvic Inflammatory Disease and Ectopic Pregnancy</gtr:title><gtr:parentPublicationTitle>Sexually Transmitted Infections</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/23035cabd35e95b67b8c61c73f200758"><gtr:id>23035cabd35e95b67b8c61c73f200758</gtr:id><gtr:otherNames>Price M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/884005FC-189A-489D-8B96-A4FF5A45CE33"><gtr:id>884005FC-189A-489D-8B96-A4FF5A45CE33</gtr:id><gtr:title>Proportion of Pelvic Inflammatory Disease Cases Caused by Chlamydia trachomatis: Consistent Picture From Different Methods.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b5f8e247f0398fb1f6fc73be32a5ab2"><gtr:id>6b5f8e247f0398fb1f6fc73be32a5ab2</gtr:id><gtr:otherNames>Price MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7930CD8-8D3A-4CEA-BE38-A2FC853F9E7A"><gtr:id>D7930CD8-8D3A-4CEA-BE38-A2FC853F9E7A</gtr:id><gtr:title>How much tubal factor infertility is caused by Chlamydia? Estimates based on serological evidence corrected for sensitivity and specificity.</gtr:title><gtr:parentPublicationTitle>Sexually transmitted diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b5f8e247f0398fb1f6fc73be32a5ab2"><gtr:id>6b5f8e247f0398fb1f6fc73be32a5ab2</gtr:id><gtr:otherNames>Price MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0148-5717</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8AF6D5C7-56B8-4F10-B04B-5AB4849305E8"><gtr:id>8AF6D5C7-56B8-4F10-B04B-5AB4849305E8</gtr:id><gtr:title>Pelvic inflammatory disease and salpingitis: incidence of primary and repeat episodes in England.</gtr:title><gtr:parentPublicationTitle>Epidemiology and infection</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6b5f8e247f0398fb1f6fc73be32a5ab2"><gtr:id>6b5f8e247f0398fb1f6fc73be32a5ab2</gtr:id><gtr:otherNames>Price MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0950-2688</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0801947</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>34</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>2EEE0958-6BE1-4D16-B86B-5D954CD37219</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Renal and Urogenital</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>FA7AA693-7EDD-4A7E-8CA3-6B5658FBF717</gtr:id><gtr:percentage>33</gtr:percentage><gtr:text>Reproductive Health and Childbirth</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>FB395309-E202-4FE8-87B0-041A3D72D4D4</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>2.5  Research design and methodologies (aetiology)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>B7F5A9CA-62C7-4E68-A2B2-3D6CCA85E16B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>7.3  Management and decision making</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>90487A08-C473-4CEB-B6D9-011A74AD06CF</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>8.4  Research design and methodologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>